Informazioni
Non ci sono recensioni
Punto di Riferimento
per Medici e Operatori Sanitari
per Medici e Operatori Sanitari
LIBRERIA STUDIUM
Renal Cell Carcinoma
Molecular Targets and Clinical Applications
Bukowski, Figlin, Motzer
Editore
Springer
Anno
2015
Pagine
613
ISBN
9781493916214
150,00 €
- Thoroughly updated edition focusing on new and recent developments in renal cell carcinoma
- Provides updated information on the rapidly evolving field of renal cell carcinoma personalized medicine, with an emphasis on novel targets and therapy
- Discusses the significant amount of new biologic and clinical information such as refinement of the RCC systemic treatment paradigm, immunoregulatory abnormalities in RCC, and adjuvant and neoadjuvant therapy
The third edition of this critically acclaimed book has updated and expanded the survey of clinical, biological and pathological management of localized and advanced renal cell carcinoma. Internationally renowned editors and contributors explore the latest developments in molecular genetics, focusing on the novel targets that have been discovered in epithelial renal tumors.
Comprehensive and authoritative, Renal Cell Carcinoma: Molecular Targets and Clinical Applications, Third Edition is the definitive text on the rapidly evolving landscape of experimental therapeutics, written and edited by leaders of the field.
Table of Contents
1 Targeted Therapy for Metastatic Renal
Cell Carcinoma: Introduction ................................................................ 1
Ronald M. Bukowski, Robert A. Figlin, and Robert J. Motzer
2 Renal Cell Carcinoma: Pathologic and Molecular
Assessment of Targets ............................................................................. 15
Ferran Algaba
3 Genomic Assessment of Renal Cancer .................................................. 39
Stephen M. Keefe, W. Kimryn Rathmell,
and Katherine L. Nathanson
4 VHL and HIF in Clear Cell Renal Cell Carcinoma:
Molecular Abnormalities and Potential Clinical Applications ........... 57
Lucy Gossage
5 PBRM1: A Critical Subunit of the SWI/SNF
Chromatin Remodeling Complex .......................................................... 111
Chung-Han Lee, Can G. Pham, and James J. Hsieh
6 Sporadic RCC: Abnormalities in Histone- Modifying Genes .............. 153
Ruhee Dere and Thai H. Ho
7 Genetic Heterogeneity in Renal Cell Carcinoma:
Clinical Implications? ............................................................................. 167
Susan A. J. Vaziri, Mahrukh K. Ganapathi, and Ram N. Ganapathi
8 First-Generation Tyrosine Kinase Inhibitors: Clinical Results .......... 177
Han Hsi Wong and Tim Eisen
9 Second-Generation Tyrosine Kinase Inhibitors
(Pazopanib) in Renal Cell Carcinoma: Current Status ....................... 207
Linda Cerbone and Cora N. Sternberg
10 Third-Generation TKIs (Axitinib, Tivozanib) in RCC:
Enhanced Efficacy and Diminished Toxicity? ...................................... 217
Hui Zhu and Brian I. Rini
11 Anti-VEGF and VEGFR Monoclonal Antibodies in RCC ................. 237
Bernard Escudier and Laurence Albiges
12 PI3-kinase, Akt, and mTOR Inhibitors in RCC .................................. 253
Daniel C. Cho and James W. Mier
13 Carbonic Anhydrase IX and Monoclonal
Antibody G250: Relevance as a Clinical and Biologic
Target in Renal Cell Carcinoma ............................................................ 263
Egbert Oosterwijk, Otto C. Boerman, Jeannette C. Oosterwijk-Wakka,
Wim J. Oyen, and Peter F. A. Mulders
14 EGFR and HER2: Relevance in Renal Cell Carcinoma ..................... 285
Sarathi Kalra and Eric Jonasch
15 The Role of Hepatocyte Growth Factor Pathway Signaling
in Renal Cell Carcinoma ........................................................................ 303
Fabiola Cecchi, Young H. Lee, Benedetta Peruzzi,
Jean-Baptiste Lattouf, and Donald P. Bottaro
16 Development of Resistance to Targeted Therapy:
Preclinical Findings and Clinical Relevance ........................................ 319
James W. Mier, Rupal S. Bhatt, David J. Panka,
and Michael B. Atkins
17 Development of Combination Therapy with Targeted Agents ........... 349
C. Lance Cowey and Thomas E. Hutson
18 Side Effects of Targeted Therapy .......................................................... 377
Luis León, Luis Miguel Antón - Aparicio, Emilio Esteban - González,
Martin Lázaro - Quintela, and Sergio Vázquez Éstevez
19 The Role of Targeted Therapy in Special Populations ........................ 417
James M. G. Larkin and Martin E. Gore
20 Immunotherapy: The Current Role of Cytokines ............................... 441
Mayer Fishman
21 Immune Checkpoint Inhibitors (Anti-CTLA4, Anti-PD-1)
in RCC ...................................................................................................... 469
Alexandra S. Bailey and David F. McDermott
22 Vaccines in RCC: Clinical and Biological Relevance ........................... 483
Devin B. Lowe, James H. Finke, Jorge A. Garcia,
and Walter J. Storkus
23 Development and Incorporation of Biomarkers
in RCC Therapeutics .............................................................................. 527
Sumanta K. Pal and Robert A. Figlin
24 Molecularly Targeted Staging Strategies
in Renal Cell Carcinoma ........................................................................ 541
Steven G. Koopman, Ali-Reza Sharif-Afshar,
Robert A. Figlin, and Hyung L. Kim
25 Clinical Prognostic Factors in Metastatic Renal Cell Carcinoma ...... 555
Nimira Alimohamed, Toni K. Choueiri, and Daniel Y. C. Heng
26 The Role of Advocacy in Renal Cell Carcinoma .................................. 569
William P. Bro and Paul Larson
Index ................................................................................................................. 601
